Upstream Bio (UPB) Free Cash Flow (2023 - 2026)

Upstream Bio's Free Cash Flow history runs 4 years deep, the most recent figure standing at -$47.9 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 16.24% year-over-year to -$47.9 million in Q1 2026; TTM through Mar 2026 was -$140.1 million, a 68.46% decrease from a year earlier, with the FY2025 full-year figure at -$133.4 million, down 123.58% from the prior year.
• Free Cash Flow retreated to -$47.9 million in Q1 2026 per UPB's latest filing, from -$30.7 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$8.0 million in Q2 2024 and bottomed at -$47.9 million in Q1 2026.
• The 4-year median for Free Cash Flow is -$21.1 million (2024), against an average of -$25.7 million.
• Across the five-year window, Free Cash Flow plunged 388.29% in 2025 and slipped 16.24% in 2026, its largest moves.
• Year by year, Free Cash Flow stood at -$16.1 million in 2023, then slipped by 24.08% to -$20.0 million in 2024, then slumped by 53.78% to -$30.7 million in 2025, then plunged by 55.66% to -$47.9 million in 2026.
• Per Business Quant, the three latest UPB Free Cash Flow figures stand at -$47.9 million (Q1 2026), -$30.7 million (Q4 2025), and -$22.2 million (Q3 2025).